Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Am J Physiol Renal Physiol
2013 Jan 01;3041:F8-F18. doi: 10.1152/ajprenal.00284.2012.
Show Gene links
Show Anatomy links
Disease-causing R1185C mutation of WNK4 disrupts a regulatory mechanism involving calmodulin binding and SGK1 phosphorylation sites.
Na T
,
Wu G
,
Zhang W
,
Dong WJ
,
Peng JB
.
???displayArticle.abstract???
The R1185C mutation in WNK4 is associated with pseudohypoaldosteronism type II (PHAII). Unlike other PHAII-causing mutations in the acidic motif, the R1185C mutation is located in the COOH-terminal region of WNK4. The goal of the study is to determine what properties of WNK4 are disrupted by the R1185C mutation. We found that the R1185C mutation is situated in the middle of a calmodulin (CaM) binding site and the mutation reduces the binding of WNK4 to Ca(2+)/CaM. The R1185C mutation is also close to serum- and glucocorticoid-induced protein kinase (SGK1) phosphorylation sites S1190 and S1217. In addition, we identified a novel SGK1 phosphorylation site (S1201) in WNK4, and phosphorylation at this site is reduced by Ca(2+)/CaM. In the wild-type WNK4, the level of phosphorylation at S1190 is the lowest and that at S1217 is the highest. In the R1185C mutant, phosphorylation at S1190 is eliminated and that at S1201 becomes the strongest. The R1185C mutation enhances the positive effect of WNK4 on the Na(+)-K(+)-2Cl(-) cotransporter 2 (NKCC2) as tested in Xenopus laevis oocytes. Deletion of the CaM binding site or phospho-mimicking at two or three of the SGK1 sites enhances the WNK4 effects on NKCC2. These results indicate that the R1185C mutation disrupts an inhibitory domain as part of the suppression mechanism of WNK4, leading to an elevated WNK4 activity at baseline. The presence of CaM binding and SGK1 phosphorylation sites in or close to the inhibitory domain suggests that WNK4 activity is subject to the regulation by intracellular Ca(2+) and phosphorylation.
Baz,
[Familial hyperkalemia syndrome (Gordon's syndrome)].
1990,
Pubmed
Bhargava,
The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action.
2001,
Pubmed
,
Xenbase
Cai,
WNK4 kinase regulates surface expression of the human sodium chloride cotransporter in mammalian cells.
2006,
Pubmed
,
Xenbase
Cartaud,
Xenopus laevis oocyte calmodulin in the process of meiotic maturation.
1980,
Pubmed
,
Xenbase
Castañeda-Bueno,
Activation of the renal Na+:Cl- cotransporter by angiotensin II is a WNK4-dependent process.
2012,
Pubmed
,
Xenbase
Chien,
Isolation and characterization of calmodulin genes from Xenopus laevis.
1984,
Pubmed
,
Xenbase
Delpire,
SPAK and OSR1, key kinases involved in the regulation of chloride transport.
2006,
Pubmed
Gordon,
Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction.
1970,
Pubmed
Hook,
Ca(2+)/CaM-dependent kinases: from activation to function.
2001,
Pubmed
Jiang,
WNK4 enhances TRPV5-mediated calcium transport: potential role in hypercalciuria of familial hyperkalemic hypertension caused by gene mutation of WNK4.
2007,
Pubmed
,
Xenbase
Kahle,
WNK4 regulates apical and basolateral Cl- flux in extrarenal epithelia.
2004,
Pubmed
,
Xenbase
Kahle,
WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion.
2003,
Pubmed
,
Xenbase
Na,
Disease-causing mutations in the acidic motif of WNK4 impair the sensitivity of WNK4 kinase to calcium ions.
2012,
Pubmed
O'Neil,
How calmodulin binds its targets: sequence independent recognition of amphiphilic alpha-helices.
1990,
Pubmed
Ohno,
Immunolocalization of WNK4 in mouse kidney.
2011,
Pubmed
PAVER,
HYPERTENSION AND HYPERPOTASSAEMIA WITHOUT RENAL DISEASE IN A YOUNG MALE.
1964,
Pubmed
Rinehart,
WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-Cl- cotransporters required for normal blood pressure homeostasis.
2005,
Pubmed
,
Xenbase
Ring,
WNK4 regulates activity of the epithelial Na+ channel in vitro and in vivo.
2007,
Pubmed
,
Xenbase
Ring,
An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis.
2007,
Pubmed
,
Xenbase
Rozansky,
Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter through an SGK1 and WNK4 signaling pathway.
2009,
Pubmed
,
Xenbase
San-Cristobal,
Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway.
2009,
Pubmed
,
Xenbase
Simon,
Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2.
1996,
Pubmed
Talati,
Effect of angiotensin II on the WNK-OSR1/SPAK-NCC phosphorylation cascade in cultured mpkDCT cells and in vivo mouse kidney.
2010,
Pubmed
Vorherr,
Interaction of calmodulin with the calmodulin binding domain of the plasma membrane Ca2+ pump.
1990,
Pubmed
Wilson,
Human hypertension caused by mutations in WNK kinases.
2001,
Pubmed
Wilson,
Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4.
2003,
Pubmed
,
Xenbase
Xia,
Mechanism of calcium gating in small-conductance calcium-activated potassium channels.
1998,
Pubmed
,
Xenbase
Xu,
Regulation of WNK1 by an autoinhibitory domain and autophosphorylation.
2002,
Pubmed
Yang,
WNK kinases regulate thiazide-sensitive Na-Cl cotransport.
2003,
Pubmed
,
Xenbase
Zhang,
WNK3 positively regulates epithelial calcium channels TRPV5 and TRPV6 via a kinase-dependent pathway.
2008,
Pubmed
,
Xenbase
de Gasparo,
International union of pharmacology. XXIII. The angiotensin II receptors.
2000,
Pubmed
van der Lubbe,
Aldosterone does not require angiotensin II to activate NCC through a WNK4-SPAK-dependent pathway.
2012,
Pubmed
